Search alternatives:
teer decrease » greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 a » 10 _ (Expand Search), 10 μ (Expand Search), 19 a (Expand Search)
teer decrease » greater decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 a » 10 _ (Expand Search), 10 μ (Expand Search), 19 a (Expand Search)
-
221
-
222
-
223
-
224
Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice.
Published 2024“…(C) In vCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.138 ± 0.065, APP/PS1 = 0.112 ± 0.035, p < 10<sup>−6</sup>, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 689 units from 6 recording sessions, n<sub>APP/PS1</sub> = 651 units from 8 recording sessions). …”
-
225
-
226
-
227
Spatial stability is decreased in APP/PS1 mice in both dCA1 and vCA1.
Published 2024“…<p>(A) In dCA1, stability score was significantly decreased in APP/PS1 mice relative to C57BL/6 mice (mean ± std: C57BL/6 = -0.009 ± 0.292, APP/PS1 = -0.1845 ± 0.256, p < 10<sup>−6</sup>, two-sided Wilcoxon rank-sum test, n<sub>C57BL/6</sub> = 295 units from 5 recording sessions, n<sub>APP/PS1</sub> = 167 units from 4 recording sessions). …”
-
228
-
229
-
230
-
231
-
232
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
-
233
-
234
A summary of the included study characteristics.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
235
-
236
-
237
-
238
-
239
-
240